Recent Finacing
Recent Raise
Emergex develops purely synthetic peptide vaccines delivered via quantum-sized nanoclusters to prime T-cell immunity and enable room-temperature storage; pipeline targets dengue and influenza, R&D based at Milton Park.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor
See the team members at Emergex Vaccines.
